Safety and Outcome of Retreatment with [177Lu]LuPSMA-I&T Radioligand Therapy (PRLT) in Metastatic Castration Resistant Prostate Cancer

被引：0
|
作者：
Santo, G. [1 ,2 ]
Di Santo, G. [1 ]
Sviridenko, A. [1 ]
Kiasatdolatabadi, M. [1 ]
Bayerschmidt, S. [1 ]
Wirth, L. [1 ]
Scherbauer, F. [1 ]
Lehmann, P. [1 ]
von Guggenberg, E. [1 ]
Decristoforo, C. [1 ]
Virgolini, I. [1 ]
机构：
[1] Med Univ Innsbruck, Dept Nucl Med, Innsbruck, Austria
[2] Magna Graecia Univ Catanzaro, Catanzaro, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-274
引用
收藏
页码：S418 / S419
页数：2
相关论文
共 50 条
  • [21] Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer EDITORIAL COMMENT
    Iagaru, Andrei
    JOURNAL OF UROLOGY, 2016, 196 (02): : 390 - 390
  • [22] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer: Safety, Efficacy and Quality of Life Assessment
    Yadav, M. P.
    Bal, C.
    Ballal, S.
    Tripathi, M.
    Damle, N. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S646 - S646
  • [23] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [24] RADIOLIGAND THERAPY WITH 177LU-PSMA-I&T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONCOLOGICAL OUTCOMES AND TOXICITY PROFILE
    Demirkol, Mehmet Onur
    Esen, Baris
    Sen, Melis
    Ucar, Burcu
    Kurtuldu, Sevgilay
    Mandel, Nil Molinas
    Bavbek, Sevil
    Falay, Okan
    Tilki, Derya
    Esen, Tarik
    JOURNAL OF UROLOGY, 2023, 209 : E125 - E126
  • [25] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [26] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [27] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [28] 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer
    Parihar, Ashwin Singh
    Hofman, Michael S.
    Iravani, Amir
    RADIOLOGY, 2023, 306 (02)
  • [29] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Ahmadzadehfar, Hojjat
    Wegen, Simone
    Yordanova, Anna
    Fimmers, Rolf
    Kuerpig, Stefan
    Eppard, Elisabeth
    Wei, Xiao
    Schlenkhoff, Carl
    Hauser, Stefan
    Essler, Markus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1448 - 1454
  • [30] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Hojjat Ahmadzadehfar
    Simone Wegen
    Anna Yordanova
    Rolf Fimmers
    Stefan Kürpig
    Elisabeth Eppard
    Xiao Wei
    Carl Schlenkhoff
    Stefan Hauser
    Markus Essler
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1448 - 1454
12345